Scandal-ridden PIP implant firm had been on FDA's radar since 2000
This article was originally published in Clinica
Executive Summary
The company at the heart of the recent French silicone breast implant furore, Poly Implant Prosthèse (PIP), had given the US FDA cause for concern as far back as 2000 when an agency inspection of the firm's facility in La Seyne-sur-mer revealed manufacturing and quality control issues.
You may also be interested in...
EU MDR Set To Rack Up Costs For Industry, German Medtechs Say
Prepare for notified body bottlenecks and skyrocketing clinical evaluation costs for medical devices as you comply with the EU Medical Device Regulation (MDR): that's what German medtech industry delegates were told at a legal and regulatory symposium last week.
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.